Table 2 Summary of (a) significant baseline factors predictive of DAS28, SDAI, and CDAI remission induction after 36 weeks of full-dose etanercept-methotrexate therapy in the open-label period and (b) significant post-baseline factors predictive of DAS28, SDAI, and CDAI remission loss at a single time point in all treatment groups in the double-blind period of the PRESERVE trial
(a) | ||
Baseline predictors of remission induction | ||
DAS28 | SDAI | CDAI |
Continuous variables | ||
• Younger age | • Younger age | • Younger age |
• Lower BMI | • Lower BMI | • Lower BMI |
• Lower DAS28, SDAI, and CDAI | • Lower DAS28, SDAI, and CDAI | • Lower DAS28, SDAI, and CDAI |
• Lower HAQ | • Lower HAQ | • Lower HAQ |
• Lower PGA and PtGA | • Lower PGA and PtGA | |
Categorical variables | ||
Younger age (>40 vs. ≤40 years; >40 to ≤65 vs. ≤40 years) | Younger age (>40 vs. ≤40 years; >40 to ≤65 vs. ≤40 years; ≥65 vs. <65 years) | Younger age (>40 vs. ≤40 years; >40 to ≤65 vs. ≤40 years; ≥65 vs. <65 years) |
• Lower DAS28 (≤4.1) | • Lower SDAI (≤15.5) | • Lower CDAI (≤14.5) |
• Lower HAQ (>0.5 to ≤1.0 vs. ≤0.5; >1.0 to ≤1.5 vs. ≤0.5; >1.5 vs. ≤0.5) | • Lower HAQ (>1.5 vs. ≤0.5) | • Lower HAQ (>1.5 vs. ≤0.5) |
(b) | ||
Post-baseline predictors of remission loss | ||
DAS28 | SDAI | CDAI |
• Lack of sustained DAS28 remission | ||
• DAS28 at wk 36 | ||
• DAS28, SDAI, and CDAI at wk 40 | • DAS28, SDAI, and CDAI at wk 40 | • DAS28 and CDAI at wk 40 |
• ∆ in DAS28, SDAI, and CDAI from wk 36-40 | • ∆ in DAS28, SDAI, and CDAI from wk 36 to 40 | • ∆ in DAS28 and CDAI from wk 36 to 40 |
• TJC and SJC at wk 40 | • TJC at wk 40 | |
• ∆ in TJC and SJC from wk 36 to 40 | • ∆ in TJC from wk 36 to 40 | |
• ESR at wk 40 | ||
• ∆ in ESR from wk 36 to 40 | ||
• ∆ in HAQ from wk 36 to 40 | • ∆ in HAQ from wk 36-40 | |
• PGA, PtGA, general health VAS, and pain VAS at wk 40 | • PGA, PtGA, general health VAS, and pain VAS at wk 40 | • PGA, PtGA, general health VAS, and pain VAS at wk 40 |
• ∆ in PGA, PtGA, general health VAS, and pain VAS from wk 36 to 40 | • ∆ in PGA, PtGA, general health VAS, and pain VAS from wk 36 to 40 | • ∆ in PGA, PtGA, general health VAS, and pain VAS from wk 36 to 40 |